Agios Pharmaceuticals (AGIO) Cash from Operations (2012 - 2026)

Agios Pharmaceuticals has reported Cash from Operations for 15 years, with the latest figure at 118920000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 6.67% year-over-year to 118920000.0; the trailing twelve-month figure through Mar 2026 stood at 380408000.0 (up 5.24% YoY), and the FY2025 full-year result was 372977000.0, up 4.33% from the prior year.
• Cash from Operations for Q1 2026 stood at 118920000.0, down from 96213000.0 in the prior quarter.
• The five-year high for Cash from Operations was 61643000.0 in Q3 2023, with the low at 133167000.0 in Q4 2024.
• Historically, Cash from Operations has averaged 87486941.18 across 5 years, with a median of 84218000.0 in 2024.
• The largest YoY upside for Cash from Operations was 56.49% in 2022 against a maximum downside of 823.8% in 2022.
• Agios Pharmaceuticals' Cash from Operations stood at 66163000.0 in 2022, then decreased by 9.56% to 72488000.0 in 2023, then slumped by 83.71% to 133167000.0 in 2024, then gained by 27.75% to 96213000.0 in 2025, then declined by 23.6% to 118920000.0 in 2026.
• The last three Cash from Operations figures came in at 118920000.0 (Q1 2026), 96213000.0 (Q4 2025), and 88151000.0 (Q3 2025), per Business Quant data.